Alisertib
Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
Millennium Pharmaceuticals, Inc.Small moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
136 Active assets in the Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pralatrexate Peking University People's Hospital | Phase 4 | BBB |
Inno-206 BeBetter Med Inc | Phase 4 | BBB |
PREDNISONE TABLETS Tarapeutics Science Inc. | Phase 4 | BBB |
Cyclophosphamide Tarapeutics Science Inc. | Phase 4 | BBB |
(+)-VINCRISTINE BeBetter Med Inc | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Alisertib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →